Table 3.
BM SUV | P value | BLR | P value | ||
Pathology | PAC/TAC | 1.49 ± 0.34 | 0.143 | 0.73 ± 0.17 | 0.081 |
PDAC | 1.54 ± 0.37 | 0.75 ± 0.16 | |||
SRC/MAC | 1.41 ± 0.32 | 0.68 ± 0.16 | |||
T stage | T1 | 1.46 ± 0.35 | 0.042 | 0.71 ± 0.16 | 0.003 |
T2-T4 | 1.54 ± 0.33 | 0.78 ± 0.17 | |||
Lymph node metastasis | Absence | 1.47 ± 0.34 | 0.123 | 0.72 ± 0.16 | 0.010 |
Presence | 1.54 ± 0.36 | 0.77 ± 0.17 | |||
FDG uptake | Negative | 1.46 ± 0.30 | 0.007 | 0.71 ± 0.14 | 0.006 |
Positive | 1.52 ± 0.38 | 0.75 ± 0.18 | |||
Recurrence | No | 1.47 ± 0.34 | 0.001 | 0.72 ± 0.16 | <0.001 |
Yes | 1.68 ± 0.36 | 0.85 ± 0.16 |
BM: Bone marrow; BLR: BM-to-liver uptake ratio; PAC: Papillary adenocarcinoma; TAC: Tubular adenocarcinoma; PDAC: Poorly-differentiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MAC: Mucinous adenocarcinoma; FDG: F-18 fluorodexoyglucose.